CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer Evolving insights into the role of local shear stress in late stent failure from neoatherosclerosis formation and plaque destabilization Long-Term Outcomes of Patients With Mediastinal Radiation–Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Systematic Review and Network Meta‐Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions Transseptal puncture versus patent foramen ovale or atrial septal defect access for left atrial appendage closure Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes
|<<... 169 170 171 172 173 174 175 ...>>|

Original Research

JOURNAL：ACC Article Link

房颤合并慢性肾病的抗凝策略

CBSMD

Pre-reading

房颤(Atrial fibrillation， AF)和慢性肾脏疾病( chronic kidney disease ，CKD)的多种致病因素常存在共通性，如高血压、糖尿病和冠状动脉疾病。当不合并CKD时，对房颤患者开展抗凝治疗是毋庸置疑的，但此做法不适用于房颤合并晚期CKD的患者群（advanced CKD）。随着CKD患者肾功能的下降，缺血性卒中和出血的危险逐渐增加，使抗凝治疗趋向复杂。现存随机对照试验尚不能得出可明确辅助临床决策的指南性意见，而观察性研究的结果相互矛盾。在最新JACC综述“Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week”中,作者概述了相关病理生理学机制,总结CKD合并AF的抗凝策略及研究进展， 并就如何在这些患者中使用口服抗凝给出建议。

该文核心要点可参阅CBSMD文献导读“Anticoagulation in Concomitant CKD and AF”。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top